Informações:
Falhas:
ID
39111
Descrição
Evaluating The Safety Of Exemestane Following 2-3 Years Of Adjuvant Tamoxifen Therapy In Postmenopausal Early Breast Cancer Patients; ODM derived from: https://clinicaltrials.gov/show/NCT01155063
Link
https://clinicaltrials.gov/show/NCT01155063
Palavras-chave
Versões (1)
- 01/12/2019 01/12/2019 -
Titular dos direitos
See clinicaltrials.gov
Transferido a
1 de dezembro de 2019
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Early Breast Cancer NCT01155063
Eligibility Early Breast Cancer NCT01155063
- StudyEvent: Eligibility
Similar models
Eligibility Early Breast Cancer NCT01155063
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Postmenopausal state
Item
postmenopausal females.
boolean
C0232970 (UMLS CUI [1])
Operative Surgical Procedure Breast Carcinoma | Neoplasm Metastasis Absent
Item
patients who have had surgical treatment for histological confirmed breast cancer that was non-metastatic at the time of the initial diagnosis.
boolean
C0543467 (UMLS CUI [1,1])
C0678222 (UMLS CUI [1,2])
C0027627 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C0678222 (UMLS CUI [1,2])
C0027627 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
Disease Free | Status post Adjuvant therapy | Tamoxifen
Item
patients who are disease-free after 2 or 3 years of adjuvant tamoxifen treatment.
boolean
C0012634 (UMLS CUI [1,1])
C0332296 (UMLS CUI [1,2])
C0231290 (UMLS CUI [2,1])
C0677850 (UMLS CUI [2,2])
C0039286 (UMLS CUI [3])
C0332296 (UMLS CUI [1,2])
C0231290 (UMLS CUI [2,1])
C0677850 (UMLS CUI [2,2])
C0039286 (UMLS CUI [3])
Estrogen receptor positive tumor
Item
patients whose tumour was estrogen receptor positive (er+).
boolean
C1562312 (UMLS CUI [1])
Informed Consent | Informed Consent Patient Representative
Item
evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
boolean
C0021430 (UMLS CUI [1])
C0021430 (UMLS CUI [2,1])
C0030701 (UMLS CUI [2,2])
C0021430 (UMLS CUI [2,1])
C0030701 (UMLS CUI [2,2])
Medical contraindication Aromasin
Item
patients for whom aromasin® treatment is contraindicated (see spc).
boolean
C1301624 (UMLS CUI [1,1])
C0876723 (UMLS CUI [1,2])
C0876723 (UMLS CUI [1,2])
Neoplasm Metastasis | Tumor Contralateral
Item
presence of metastasis or a contra lateral tumour.
boolean
C0027627 (UMLS CUI [1])
C0027651 (UMLS CUI [2,1])
C0441988 (UMLS CUI [2,2])
C0027651 (UMLS CUI [2,1])
C0441988 (UMLS CUI [2,2])
Hormone Therapy Adjuvant
Item
other adjuvant endocrine therapy.
boolean
C0279025 (UMLS CUI [1,1])
C1522673 (UMLS CUI [1,2])
C1522673 (UMLS CUI [1,2])
Cancer treatment Other
Item
another concomitant antineoplastic treatment.
boolean
C0920425 (UMLS CUI [1,1])
C0205394 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,2])
Study Subject Participation Status | Investigational New Drugs
Item
participation in a clinical trial with an investigational drug during the 30 days prior to enrolment in the study.
boolean
C2348568 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
C0013230 (UMLS CUI [2])